List view / Grid view
28 April 2014 | By Roche
First anti IL-6 receptor biologic now available for subcutaneous and intravenous administration for both monotherapy and combination therapy...
25 April 2014 | By Roche
Expanded indication makes cobas HPV Test the only test approved in U.S. that can be used instead of Pap in first-line primary screening in women 25 and older...
7 April 2014 | By Roche
IQuum’s unique products will allow Roche to quickly enter the point of care segment of molecular diagnostics...
24 March 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration approved Xolair (omalizumab) for the treatment of chronic idiopathic urticaria, a form of chronic hives...
13 March 2014 | By Roche
Roche announced that the U.S. Food and Drug Administration Microbiology Devices Panel of the Medical Devices Advisory Committee recommended unanimously that the benefits of the cobas HPV Test...
7 March 2014 | By Roche
Diagnostics division strengthens its position in the serology market and expands its immunoassay portfolio in infectious disease...
5 March 2014 | By Roche
Roche presented new data from the LUTE / VERSE phase IIb studies investigating lebrikizumab in patients with severe uncontrolled asthma...
4 March 2014 | By Roche
Roche announced that its Ordinary Annual General Meeting has voted in favour of all of the Board of Directors’ proposals...
3 March 2014 | By Roche
Roche announced that an independent data monitoring committee has recommended that the phase III METLung study be stopped due to a lack of clinically meaningful efficacy...
21 February 2014 | By Roche
New automated CINtec PLUS test improves the detection of cervical pre-cancer...
30 January 2014 | By Roche
Roche’s CEO Severin Schwan: “2013 was a very good year for Roche. We exceeded our financial targets with strong demand for our existing products and positive uptake of recently launched medicines and diagnostics...
21 January 2014 | By Roche
Roche announced that two phase III studies of its investigational medicine bitopertin (RG1678) in adults with persistent, predominant negative symptoms of schizophrenia failed to meet their primary endpoints...
20 December 2013 | By Roche
“This positive opinion from the CHMP is a step toward providing physicians and patients the flexibility to choose whether intravenous or subcutaneous RoActemra treatment..."
22 November 2013 | By Novo Nordisk
Insulin aspart PumpCart® is a 1.6 ml prefilled insulin pump cartridge containing the rapid-acting insulin aspart...
20 November 2013 | By Roche
Kadcyla is indicated as a single agent for the treatment of adults with HER2-positive, unresectable locally advanced or metastatic breast cancer...
